Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine Candidates
Abstract
Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease, and an effective vaccine is not available. In this study, we compared the immunogenicity and protection efficacy of recombinant proteins corresponding to different domains of the SARS-coronavirus spike protein. Trimeric recombinant proteins were created by fusing the foldon domain derived from T4 bacteriophage to the carboxy-termini of individual domains of the spike protein. While the full-length ectodomain (S) of the spike protein, the full-length ectodomain fused to foldon (S-foldon), the S1 domain (S1), S1-foldon, and the S2 domain(S2) antigens all elicited comparable antibody titers as measured by ELISA, S-foldon induced a significantly higher titer of neutralizing antibody and S2 protein did not elicit virus neutralizing antibodies. When tested in a mouse virus replication model, all the mice vaccinated with the S1, S1-foldon, S, or S-foldon were completely protected.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Enjuanes LDediego MLAlvarez EDeming DSheahan TBaric TR. Vaccine to prevent severe acute respiratory syndrome coronavirus-induced diseaseVirus Res200813345-62. 1. Enjuanes L, Dediego ML, Alvarez E, Deming D, Sheahan T, and Baric TR. Vaccine to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res 2008;133:45–62.
2.
Roper LRRehm KE. SARS vaccines: Where are we?Expert Rev Vaccines20098887-898. 2. Roper LR, and Rehm KE. SARS vaccines: Where are we? Expert Rev Vaccines 2009;8:887–898.
3.
Marra MAJones SJAstell CR et al. The genome sequence of the SARS-associated coronavirusScience20033001399-1404. 3. Marra MA, Jones SJ, Astell CR, et al. The genome sequence of the SARS-associated coronavirus. Science 2003;300:1399–1404.
4.
Rota PAOberste MSMonroe SS et al. Characterization of a novel coronavirus associated with severe acute respiratory syndromeScience20033001394-1399. 4. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300:1394–1399.
5.
Hofmann HPöhlmann S. Cellular entry of the SARS coronavirusTrends Microbiol200412466-472. 5. Hofmann H, and Pöhlmann S. Cellular entry of the SARS coronavirus. Trends Microbiol 2004;12:466–472.
6.
Du LHe YZhou YLiu SZheng BJJiang S. The spike protein of SARS-CoV. A target for vaccine and therapeutic developmentNat Rev Microbiol2009226-236. 6. Du L, He Y, Zhou Y, Liu S, Zheng BJ, and Jiang S. The spike protein of SARS-CoV. A target for vaccine and therapeutic development. Nat Rev Microbiol 2009;226–236.
7.
Song HCSeo MYStadler K et al. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoproteinJ Virol20047810328-10335. 7. Song HC, Seo MY, Stadler K, et al. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol 2004;78:10328–10335.
8.
Tao YStrelkov SVMesyanzhinov VVRossmann MG. Structure of bacteriophage T4 fibritin: A segmented coiled coil and the role of the C-terminal domainStructure19975789-798. 8. Tao Y, Strelkov SV, Mesyanzhinov VV, and Rossmann MG. Structure of bacteriophage T4 fibritin: A segmented coiled coil and the role of the C-terminal domain. Structure 1997;5:789–798.
9.
Yang ZYKong WPHuang Y et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature2004428561-564. 9. Yang ZY, Kong WP, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004;428:561–564.
10.
Ksiazek TGErdman DGoldsmith CS et al. and SARS Working Group. A novel coronavirus associated with severe acute respiratory syndromeN Engl J Med20033481953-1966. 10. Ksiazek TG, Erdman D, Goldsmith CS, et al. and SARS Working Group. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953–1966.
11.
Reed LJMuench H. A simple method of estimating fifty percent endpointsAm J Hyg193827493-497. 11. Reed LJ, and Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938;27:493–497.
12.
Kam YMKien FRoberts A et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitroVaccine200725729-740. 12. Kam YM, Kien F, Roberts A, et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine 2007;25:729–740.
13.
Zhou ZPost PChubet R et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in miceVaccine2006243624-3631. 13. Zhou Z, Post P, Chubet R, et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 2006;24:3624–3631.
14.
Kammerer RAMechling DSchulthess T et al. Stabilization of short collagen-like triple helices by protein engineeringJ Mol Biol20013081081-1089. 14. Kammerer RA, Mechling D, Schulthess T, et al. Stabilization of short collagen-like triple helices by protein engineering. J Mol Biol 2001;308:1081–1089.
15.
Roberts ALamirande EWVogel L et al. Animal models and vaccines for SARS-CoV infectionVirus Res200813320-32. 15. Roberts A, Lamirande EW, Vogel L, et al. Animal models and vaccines for SARS-CoV infection. Virus Res 2008;133:20–32.
16.
Keng CTZhang AShen S et al. Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: Implications for the development of vaccines and antiviral agentsJ Virol2005793289-3296. 16. Keng CT, Zhang A, Shen S, et al. Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: Implications for the development of vaccines and antiviral agents. J Virol 2005;79:3289–3296.
17.
Lai SCChong PCYeh CT et al. Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV)J Biomed Sci200512711-727. 17. Lai SC, Chong PC, Yeh CT, et al. Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV). J Biomed Sci 2005;12:711–727.
18.
Wang SChou THSakhatskyy PV et al. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression systemJ Virol2005791906-1910. 18. Wang S, Chou TH, Sakhatskyy PV, et al. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol 2005;79:1906–1910.
19.
Zhang HWang GLi J et al. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodiesJ Virol2004786938-6945. 19. Zhang H, Wang G, Li J, et al. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol 2004;78:6938–6945.
20.
Guo YSun SWang KZhang SZhu WChen Z. Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirusDNA Cell Biol200524510-515. 20. Guo Y, Sun S, Wang K, Zhang S, Zhu W, and Chen Z. Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus. DNA Cell Biol 2005; 24:510–515.
21.
Zeng FChow KYHon CC et al. Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragmentsBiochem Biophys Res Commun20043151134-1139. 21. Zeng F, Chow KY, Hon CC, et al. Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. Biochem Biophys Res Commun 2004;315:1134–1139.
22.
Cavanagh DDavis PJDarbyshire JHPeters RW. Coronavirus IBV: Virus retaining spike glycopolypeptide S2 but not S1 is unable to induce virus-neutralizing or haemagglutination-inhibiting antibody, or induce chicken tracheal protectionJ Gen Virol1986671435-1442. 22. Cavanagh D, Davis PJ, Darbyshire JH, and Peters RW. Coronavirus IBV: Virus retaining spike glycopolypeptide S2 but not S1 is unable to induce virus-neutralizing or haemagglutination-inhibiting antibody, or induce chicken tracheal protection. J Gen Virol 1986;67:1435–1442.
23.
Delmas BRasschaert DGodet MGelfi JLaude H. Four major antigenic sites of the coronavirus transmissible gastroenteritis virus are located on the amino-terminal half of spike glycoprotein SJ Gen Virol1990711313-1323. 23. Delmas B, Rasschaert D, Godet M, Gelfi J, and Laude H. Four major antigenic sites of the coronavirus transmissible gastroenteritis virus are located on the amino-terminal half of spike glycoprotein S. J Gen Virol 1990;71:1313–1323.
24.
Godet MGrosclaude JDelmas BLaude H. Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike proteinJ Virol1994688008-8016. 24. Godet M, Grosclaude J, Delmas B, and Laude H. Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein. J Virol 1994;68:8008–8016.
25.
Vautherot JFMadelaine MFBoireau PLaporte J. Bovine coronavirus peplomer glycoproteins: Detailed antigenic analyses of S1, S2, and HEJ Gen Virol1992731725-1737. 25. Vautherot JF, Madelaine MF, Boireau P, and Laporte J. Bovine coronavirus peplomer glycoproteins: Detailed antigenic analyses of S1, S2, and HE. J Gen Virol 1992;73:1725–1737.
Information & Authors
Information
Published In
Copyright
Copyright 2013, Mary Ann Liebert, Inc.
History
Published online: 10 April 2013
Published in print: April 2013
Topics
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.